AstraZeneca Q2 tops estimates, reaffirms FY25 guidance
AstraZeneca stock rose 3% premarket after beating Q2 expectations, with EPS up 27% YoY to $1.58 and revenue rising 12% to $14.46 billion. Product sales grew 11%, led by oncology and immunology drugs. The firm reaffirmed its FY25 outlook and pledged $50 billion investment in the US amid onshoring efforts under Trump's policies.